Clarius Group LLC’s Invesco NASDAQ Biotechnology ETF IBBQ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$551K Buy
19,396
+61
+0.3% +$1.66K 0.03% 192
2025
Q3
$470K Buy
19,335
+78
+0.4% +$1.79K 0.03% 217
2025
Q2
$407K Buy
19,257
+26
+0.1% +$534 0.02% 292
2025
Q1
$408K Buy
19,231
+35
+0.2% +$778 0.03% 281
2024
Q4
$413K Buy
19,196
+54
+0.3% +$1.25K 0.03% 252
2024
Q3
$455K Buy
19,142
+72
+0.4% +$1.72K 0.03% 236
2024
Q2
$434K Buy
19,070
+42
+0.2% +$918 0.03% 237
2024
Q1
$422K Buy
19,028
+38
+0.2% +$842 0.03% 260
2023
Q4
$416K Buy
18,990
+46
+0.2% +$905 0.03% 272
2023
Q3
$375K Buy
18,944
+39
+0.2% +$796 0.04% 275
2023
Q2
$386K Buy
18,905
+42
+0.2% +$879 0.03% 326
2023
Q1
$390K Buy
18,863
+35
+0.2% +$733 0.03% 310
2022
Q4
$397K Buy
18,828
+38
+0.2% +$786 0.04% 303
2022
Q3
$356K Buy
18,790
+38
+0.2% +$754 0.04% 294
2022
Q2
$353K Hold
18,752
0.04% 284
2022
Q1
$445K Hold
18,752
0.04% 262
2021
Q4
$445K Hold
18,752
0.04% 262
2021
Q3
$480K Buy
+18,752
New +$494K 0.04% 218

Other funds holding IBBQ

Clarius Group LLC's IBBQ Position: Q4 2025 in Review

Clarius Group LLC increased its Invesco NASDAQ Biotechnology ETF (IBBQ) stake by 0.32% in Q4 2025, buying an estimated $1.66K and bringing the position to 19,396 shares worth $551K. The position accounts for 0.03% of the portfolio, ranked #192.

Clarius Group LLC first reported a position in IBBQ in Q3 2021 and has held it in 18 quarters since. 31 funds tracked by Wall St. Rank hold IBBQ as of Q4 2025.

  • Clarius Group LLC held 19,396 shares of Invesco NASDAQ Biotechnology ETF worth $551K as of Q4 2025.
  • Clarius Group LLC bought 61 Invesco NASDAQ Biotechnology ETF shares in Q4 2025, an estimated $1.66K.
  • Invesco NASDAQ Biotechnology ETF made up 0.03% of Clarius Group LLC's portfolio in Q4 2025, its #192 holding.
  • Clarius Group LLC first reported a position in Invesco NASDAQ Biotechnology ETF in Q3 2021 and has held it in 18 quarters since.
  • 31 funds tracked by Wall St. Rank held Invesco NASDAQ Biotechnology ETF as of Q4 2025.

Based on Clarius Group LLC's 13F filing for Q4 2025, filed 14 Jan 2026.